OTR Therapeutics completed a USD 100 million Series A financing closed in June 2025. The round was backed by True Light Capital, a wholly-owned subsidiary of Temasek, LAV, Pfizer Ventures and Sirona Capital.

The proceeds of the financing will advance OTR's pipeline of differentiated programmes that target significant treatment gaps in immunology and inflammation, oncology, and other disease areas. The funds will also expand OTR's R&D hub capability, which emphasises both scientific excellence and strategic partnership agility to foster expedited development of high-impact therapies.

OTR also announced the acquisition of a pre-clinical programme with the best-in-class potential for neurological diseases with high unmet needs. This acquisition is part of the company's strategic and ongoing efforts to identify and advance promising early-stage assets into global clinical development, alongside its internal proprietary discovery programmes to address a broader range of critical patient needs.

"The rapidly evolving global pharmaceutical R&D landscape demands greater novelty, speed and efficiency. At OTR, we aim to build a next-generation biotech model that delivers unprecedented R&D and capital efficiency. It enables us to stay agile while remaining rigorously focused on propelling novel, differentiated drug candidates through global clinical translation in a disciplined and efficient manner. We are grateful for the strong support from our investors and their confidence in our vision and capability to deliver transformative therapies for patients," said Dr Zhui Chen, Founder and CEO, OTR Therapeutics.

Co-founded by Zhui Chen, PhD; Shannon Chuai, PhD; and Yuan Shi, PhD, OTR Therapeutics is led by a team of seasoned drug hunters and entrepreneurs in the biotech and pharmaceutical industries with a proven track record of delivering breakthrough innovation, operational excellence and financial success.

Yi Shi, Managing Director, LAV, said, "We believe the biopharma industry is shifting towards more capital-efficient and specialised R&D models. OTR Therapeutics is at the forefront of this evolution, demonstrating how a focused, integrated framework can expedite the journey of translating early-stage innovation into global clinical development."

Founded in March 2025, OTR Therapeutics is establishing a novel, scalable and capital-efficient model that synergizes internal R&D with strategic curation of high-potential external innovation. This approach enables the company to focus on scientific rigor and operational agility, leveraging its regional insights and the development efficiency of the local ecosystem to accelerate innovative therapies to patients worldwide.

Michael Baran, Partner, Pfizer Ventures, added, "Pfizer Ventures identifies and invests in emerging companies who are developing innovative medicines and technologies that have the potential to shape the future of our industry. To this end, we're pleased to be able to support OTR Therapeutics as it scales its R&D capabilities and builds a portfolio of potentially transformative therapies."